Cardarine Overview, Dosing & Safety | Peptide Database

Cardarine (GW501516)

PPAR-delta Agonist | Endurance & Fat Metabolism

Community Research

Join others researching Cardarine — share findings, ask questions, and learn from real experiences

Cardarine (GW501516) is a synthetic PPAR-delta (peroxisome proliferator-activated receptor delta) agonist originally developed by GlaxoSmithKline and Ligand Pharmaceuticals in the early 2000s for the treatment of metabolic and cardiovascular diseases, including dyslipidemia, obesity, and diabetes. Despite being almost universally categorized alongside SARMs in the performance enhancement market, Cardarine is not a selective androgen receptor modulator and does not bind to the androgen receptor at all. Its mechanism is entirely distinct: it activates PPAR-delta, a nuclear receptor that regulates fatty acid oxidation, energy expenditure, and lipid metabolism. In preclinical studies, Cardarine demonstrated remarkable effects on endurance capacity, fat oxidation, and lipid profiles. However, development was abandoned by GSK in 2007 after preclinical toxicology studies in rodents revealed an increased incidence of tumors across multiple organ systems when the compound was administered at supratherapeutic doses over extended periods. This cancer signal remains the central controversy and safety concern surrounding Cardarine. The compound has never been approved for human use by any regulatory agency, and no clinical trials have been completed. It is classified as a prohibited substance by the World Anti-Doping Agency (WADA). Despite these concerns, Cardarine continues to be widely available through research chemical suppliers and is used in performance enhancement contexts for its potent endurance-boosting and fat-burning properties.

Cardarine acts as a potent and highly selective agonist of PPAR-delta, a nuclear hormone receptor expressed in skeletal muscle, liver, adipose tissue, and the gastrointestinal tract. Upon binding to PPAR-delta, Cardarine triggers a conformational change that promotes heterodimerization with retinoid X receptor (RXR), and the resulting complex binds to PPAR response elements (PPREs) in the promoter regions of target genes. This transcriptional activation upregulates a suite of genes involved in fatty acid oxidation, mitochondrial biogenesis, and energy uncoupling. In skeletal muscle, PPAR-delta activation by Cardarine shifts the metabolic fuel preference from glucose toward fatty acids, dramatically increasing the rate of beta-oxidation. This metabolic reprogramming effectively transforms type II (fast-twitch, glycolytic) muscle fibers toward a more oxidative phenotype, similar to type I (slow-twitch) fibers, which underpins the compound's dramatic effects on endurance capacity. Preclinical studies in mice demonstrated that GW501516 treatment increased running endurance by up to 68% compared to controls. In the liver and adipose tissue, PPAR-delta activation by Cardarine promotes fatty acid catabolism and reduces lipogenesis, resulting in reduced body fat storage and improved lipid profiles (increased HDL, decreased LDL, reduced triglycerides). Critically, Cardarine does not interact with the androgen receptor, does not suppress the hypothalamic-pituitary-gonadal (HPG) axis, and does not affect endogenous testosterone production. This non-hormonal mechanism means it does not cause testosterone suppression and does not require post-cycle therapy.

Molecular Data

Research Indications

Cardarine's most pronounced effect is on aerobic endurance. By upregulating fatty acid oxidation and promoting oxidative muscle fiber characteristics, it substantially increases the duration and intensity at which aerobic exercise can be sustained. Preclinical studies showed up to a 68% increase in running distance in treated mice. Anecdotal reports from human users consistently describe marked improvements in cardiovascular endurance within 1-2 weeks of use.

By promoting fatty acid oxidation as the primary metabolic fuel source and reducing lipogenesis, Cardarine accelerates fat loss independently of caloric restriction. The shift toward fat as a fuel substrate means greater caloric expenditure from stored adipose tissue during both exercise and rest. Users report noticeable reductions in body fat, particularly when combined with a structured training program.

Cardarine consistently improves blood lipid markers in preclinical and early human data. It increases HDL cholesterol, decreases LDL cholesterol, and reduces triglycerides. This property makes it of particular interest as a co-administration agent during SARM or anabolic steroid cycles, which typically worsen lipid profiles.

Cardarine was originally developed for the treatment of dyslipidemia and metabolic syndrome. Early Phase I/II human data demonstrated favorable shifts in lipid profiles at low doses. Development was halted before efficacy trials could be completed due to the carcinogenicity findings in rodent models.

Preclinical data supported Cardarine's potential for treating obesity and metabolic syndrome through enhanced fat oxidation and improved insulin sensitivity. These indications were never pursued to clinical completion due to safety concerns.

Dosing Protocols

Cardarine is administered exclusively via the oral route. It is available as a liquid solution (typically dissolved in PEG-400 or similar carrier) or in capsule form from research chemical suppliers. The compound has high oral bioavailability. Its half-life of approximately 16-24 hours supports once-daily dosing. Steady-state plasma concentrations are achieved within a few days of consistent administration.

Research Dose - Standard

10 mg/day

Once daily

Oral (liquid or capsule)

Research Dose - Upper Range

20 mg/day

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Headaches (typically transient, most common in the first week)

Mild gastrointestinal discomfort (nausea, loose stools, or stomach upset, usually dose-dependent and transient)

Stop Signs - Discontinue if:

Any unusual lumps, masses, or unexplained weight loss (given the carcinogenicity concern from preclinical data)

Severe or persistent gastrointestinal symptoms

Unexplained fatigue or malaise

Signs of allergic reaction: rash, swelling, difficulty breathing

Contraindications

Personal or family history of cancer (the rodent carcinogenicity data warrants extreme caution in individuals with elevated cancer risk)

Pregnancy or potential pregnancy

Breastfeeding

Pre-existing liver disease (limited safety data)

Individuals under 18 years of age

Quality Checklist

Good Signs

Third-party lab tested with certificate of analysis (COA) showing purity above 98%

Clearly labeled with compound name, concentration, batch number, and expiration date

Solution is clear and free of particulate matter or discoloration

Sold as a research chemical with appropriate disclaimers (not marketed for human consumption)

Supplier provides HPLC or mass spectrometry verification of identity and purity

Warning Signs

No third-party testing or certificate of analysis available

Sold in pre-made capsules without verifiable dosing accuracy

Marketed with explicit performance enhancement claims (regulatory red flag)

Unusually low pricing compared to established research chemical suppliers

Labeled as a SARM (incorrect classification may indicate low supplier knowledge or intentional mislabeling)

Bad Signs

Cloudy, discolored, or precipitated solution indicating degradation or contamination

No labeling, incorrect labeling, or missing batch/lot information

Supplier has no verifiable reputation, reviews, or testing history

Product tested by independent labs showing underdosed, mislabeled, or contaminated contents

Contains unlisted active ingredients or adulterants

Sold by a source that also sells controlled substances (legal risk indicator)

Frequently Asked Questions

Does Cardarine suppress testosterone like SARMs do?

No. Cardarine is NOT a SARM and does not bind the androgen receptor. It does not suppress the HPTA axis or affect testosterone production. This is a major advantage—you get endurance and fat-loss benefits without testosterone suppression or the need for post-cycle therapy.

What's the cancer concern with Cardarine?

In 2-year rodent studies, GW501516 caused tumors across multiple organ systems at supratherapeutic doses (10-40x equivalent human dose). Development was abandoned in 2007 due to this cancer signal. The critical debate: rodent doses and lifespans are not directly translatable to humans at 10-20 mg/day for 8-12 weeks, but the risk is unresolved and cannot be ruled out.

How quickly does Cardarine improve endurance?

Improvements in cardiovascular endurance are often noticeable within the first week to two weeks. Users report being able to sustain higher-intensity cardio for longer durations. The full effects plateau around 4-8 weeks. This rapid onset distinguishes Cardarine from many other endurance-enhancing compounds.

Can I stack Cardarine with testosterone or SARMs?

Yes. Cardarine is fully compatible with testosterone, SARMs, and other compounds due to its non-hormonal mechanism. It's commonly stacked with RAD-140 or LGD-4033 for body recomposition. Cardarine may even partially offset the negative lipid effects caused by some SARMs and anabolic steroids.

References

Demonstrated that GW501516 administration significantly enhanced running endurance in mice through metabolic reprogramming favoring fatty acid oxidation over glycolysis. Metabolomic profiling revealed widespread changes in lipid, amino acid, and energy metabolism pathways consistent with PPAR-delta activation.

Showed that PPAR-delta activation reprograms skeletal muscle metabolism to preferentially oxidize fatty acids, sparing glucose and glycogen. GW501516-treated mice ran approximately 68% longer and 70% farther than untreated controls. The study demonstrated that PPAR-delta acts as an exercise mimetic at the transcriptional level.

One of the few published human studies on GW501516. In healthy volunteers, low-dose Cardarine over 2 weeks increased HDL cholesterol, reduced LDL cholesterol, reduced triglycerides, and reduced apolipoprotein B levels. The compound was well tolerated in this short-term study at low doses.

Reviewed the complex and sometimes contradictory evidence regarding PPAR-delta activation and cancer. While GW501516 promoted tumorigenesis in some rodent models, particularly in the gastrointestinal tract, the relationship between PPAR-delta activation and cancer is not straightforward, with some studies suggesting anti-tumorigenic effects in certain contexts. The review highlighted the need for further research to understand the tissue-specific and dose-dependent effects.

Demonstrated that PPAR-delta activation by GW501516 promoted intestinal polyp growth in APC-min mice (a genetic model predisposed to colorectal cancer). This was one of the early studies raising cancer concerns about PPAR-delta agonists and contributed to the eventual abandonment of GW501516 clinical development.

Related Peptides

Cardarine is fully compatible with exogenous testosterone. It does not interfere with androgen receptor signaling, does not affect testosterone metabolism, and does not contribute to HPG axis suppression. The lipid-improving properties of Cardarine may partially offset the negative lipid effects of exogenous testosterone use.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.